



1647

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: M. Rigdon Lentz

Serial No.: 09/709,045

Art Unit: 1647

Filed: November 10, 2000

Examiner: Not Yet Assigned

#11
B.G.J
10/16/02

For: *METHOD AND SYSTEM TO REMOVE CYTOKINE INHIBITOR IN PATIENTS*

Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicant submits a Supplemental Information Disclosure Statement, including one (1) page of Form PTO-1449 and a copy of one document cited therein.

This Supplemental Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any additional fees to Deposit Account No. 50-1868.

U.S. Patents

Number
6,379,708

Publication Date
04-30-2002

Patentee
Howell, et al.

Class/Subclass
424/529

RECEIVED

SEP 04 2002

1
TECH CENTER 1600/2900

U.S.S.N.: 09/709,045
Filed: November 10, 2000
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicant invites the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicant is of the opinion that his claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284

Dated: September 27, 2002


HOLLAND & KNIGHT LLP
One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400
404-817-8500
FAX 404-817-0470
www.hklaw.com

U.S.S.N.: 09/709,045
Filed: November 10, 2000
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Certificate of Mailing under 37 CFR §1.8(a)

I hereby certify that this Supplemental Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: September 27, 2002


Erica C. Boughner

ATL1 #545993 v1



SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT CHECKLIST

Client and Matter Name: LEN 102

Client #/ Matter #: 077829-00006

Attorney and Due Date Pabst

Check Requested N/A

I have checked the following sources for references to be cited in the IDS and/ or Supplemental IDS:

☒ Application and PTO Correspondence File LEN 102

☐ Application

☒ IDS/ Supp. IDS LEN 102

☐ Office Action/ PTO-892

☐ Other _____


☐ PCT File

☒ PCT Written Opinion LEN 102

☒ International Search Report LEN 102

☒ Other Patrea L. Pabst

Suggestions/Requests for other sources:


Erica C. Boughner

RECEIVED

SEP 04 2002

TECH CENTER 1600/2900